ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Enzon, NeuroSearch To Slash Jobs

by Ann M. Thayer
October 3, 2011 | APPEARED IN VOLUME 89, ISSUE 40

Enzon Pharmaceuticals is slashing its workforce almost in half and cutting its operating costs to better align resources with its R&D activities. By June 2012, after the cuts go into effect, the New Jersey company will have 47 employees. Enzon uses customized PEGylation linker technology and mRNA-targeting agents to develop cancer therapeutics. Separately, Denmark’s NeuroSearch will reduce its workforce from almost 200 currently to about 50 a year from now. The firm is dropping most activities to focus on a Phase III study of its Huntington’s disease drug.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment